跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
VEMLIDY - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
VEMLIDY
Authorized
STANDARD
VEMLIDY
gilead sciences canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
50501b06224e0bb6
Company
gilead sciences canada inc
Type
Standard
Approval Details
Approval Id
50501b06224e0bb6
Drug Approval Canada Name
VEMLIDY
Product Name
VEMLIDY
Status
Marketed
Status Date
2017-06-20
Original Market Date
2017-06-20
Din
02464241
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
08:18.08.20
Atc Original
J05AF13 TENOFOVIR ALAFENAMIDE
Atc Name
j 05 af 13
Aig Number
0159070001
Company Name
gilead sciences canada inc
Company Address
400, 6925 Century Avenue, Mississauga, Ontario, Canada, L5N 7K2
Active Ingredients
TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)
25 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
50501b06224e0bb6
Type
Standard
Back to Health Canada Approvals